RBC Europe’s United Therapeutics UTHR Stock Holding History

RBC Europe’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,800	Closed	-$332K	–	1132
2021 Q3	$332K	Sell	1,800 -1,200	-40%	-$236K	0.01%	234
2021 Q2	$538K	Hold	3,000	–	–	0.02%	193
2021 Q1	$502K	Hold	3,000	–	–	0.03%	182
2020 Q4	$455K	Hold	3,000	–	–	0.03%	187
2020 Q3	$303K	Hold	3,000	–	–	0.02%	211
2020 Q2	$363K	Hold	3,000	–	–	0.03%	184
2020 Q1	$284K	Hold	3,000	–	–	0.03%	176
2019 Q4	$264K	Hold	3,000	–	–	0.02%	210
2019 Q3	$239K	Hold	3,000	–	–	0.02%	221
2019 Q2	$234K	Hold	3,000	–	–	0.02%	231
2019 Q1	$352K	Hold	3,000	–	–	0.04%	184
2018 Q4	$327K	Hold	3,000	–	–	0.04%	175
2018 Q3	$384K	Hold	3,000	–	–	0.04%	183
2018 Q2	$339K	Hold	3,000	–	–	0.04%	195
2018 Q1	$337K	Hold	3,000	–	–	0.04%	195
2017 Q4	$444K	Hold	3,000	–	–	0.05%	169
2017 Q3	$352K	Buy	+3,000	New	+$383K	0.05%	183

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

RBC Europe's UTHR Position: Q4 2021 in Review

RBC Europe sold out of United Therapeutics (UTHR) in Q4 2021, closing a stake of 1,800 shares — an estimated $332K sold.

RBC Europe first reported a position in UTHR in Q3 2017 and held it in 17 quarters. The position peaked at $538K in Q2 2021. 415 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

RBC Europe reported no remaining United Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 1,800 United Therapeutics shares in Q4 2021, an estimated $332K.
RBC Europe first reported a position in United Therapeutics in Q3 2017 and held it in 17 quarters.
RBC Europe's United Therapeutics position peaked at $538K in Q2 2021.
415 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.